# CellFE

- **Section**: news
- **Answer**: CellFE: 16 headlines on record, 0 headlines in the last 90 days. Its story counts 12 milestones.
- **As of**: 2026-11-18
- **Cite**: CellFE, News. Alion, Nov 18, 2026. https://alion.io/company/cellfebiotech/news
- **License**: CC BY-SA 4.0

## Company

- **Id**: 3782840
- **Name**: CellFE
- **Domain**: cellfebiotech.com
- **Url**: <https://alion.io/company/cellfebiotech>

## Figures

- Label: Headlines; Value: 16
- Label: In 90 days; Value: 0
- Label: Milestones; Value: 12

## Blocks

- **Headlines** — Key: news; Source: the outlets named on each headline, each story once; Rows: 13
- **Milestones** — Key: story; Source: Each milestone is dated by its source: registers, filings, the press; Rows: 12

## News

- [CellFE and Made Scientific Announce Strategic Collaboration to Advance Non-viral Gene Editing for T Cell Therapies](https://cellfebiotech.com/cellfe-and-made-scientific-announce-strategic-collaboration-to-advance-non-viral-gene-editing-for-t-cell-therapies/) — Date: 2025-05-13; Kind: Blog
- [CellFE Partners with DKFZ and TcellTech to Advance DNA Vector Genetic Engineering for Cellular Therapies](https://cellfebiotech.com/cellfe-partners-with-dkfz-and-tcelltech-to-advance-dna-vector-genetic-engineering-for-cellular-therapies/) — Date: 2025-04-30; Kind: Blog
- [Application Note: Efficient Gene Editing of iPSCs](https://cellfebiotech.com/application-note-efficient-gene-editing-of-ipscs/) — Date: 2025-03-04; Kind: Blog
- [CellFE Announces Launch of First-in-Class T-Rest ("Resting T Cell Kit") for Breakthrough CAR-T Cell Therapy Manufacturing](https://finance.yahoo.com/news/cellfe-announces-launch-first-class-130000258.html) — Date: 2025-01-22; Kind: News; Source: YahooFinance
- [Application Note: CellFE CAR T Cell Editing](https://cellfebiotech.com/cellfe-car-t-cell-editing-doc/) — Date: 2025-01-17; Kind: Blog
- [CellFE(R) and Syenex Collaborate to Advance Cell Engineering with Hybrid Gene Editing Workflow](https://marketwatch.com/press-release/cellfe-r-and-syenex-collaborate-to-advance-cell-engineering-with-hybrid-gene-editing-workflow-3f843d13) — Date: 2025-01-09; Kind: Press release; Source: marketwatch.com
- [CellFE Announces Addition of Life Science Tools Veteran Mike Rice to Board of Directors](https://cellfebiotech.com/cellfe-appoints-mike-rice-to-board-of-directors/) — Date: 2024-06-28; Kind: Blog
- [CellFE Announces Presentations at International Society of Gene & Cell Therapy (ISCT) 2024 Annual Meeting](https://cellfebiotech.com/cellfe-announces-presentations-at-international-society-of-gene-cell-therapy-isct-2024-annual-meeting/) — Date: 2024-05-29; Kind: Blog
- [CellFE Announces Presentations at Upcoming International Society of Gene & Cell Therapy (ISCT) 2024 Annual Meeting](https://marketwatch.com/press-release/cellfe-announces-presentations-at-upcoming-international-society-of-gene-cell-therapy-isct-2024-annual-meeting-f6b41a59) — Date: 2024-05-23; Kind: Press release; Source: marketwatch.com
- [CellFE Announces May 2024 Conference Presentations](https://cellfebiotech.com/cellfe-announces-may-2024-conference-presentations/) — Date: 2024-04-26; Kind: Blog
- [Endpoints News: CellFE raises $22M Series A to advance a new cell therapy manufacturing idea](https://cellfebiotech.com/endpoints-news-cellfe-raises-22m-series-a-to-advance-a-new-cell-therapy-manufacturing-idea/) — Date: 2023-09-27; Kind: Press release
- [CellFE announces launch of novel microfluidic cellular engineering platform at ASGCT 2023 Annual Meeting](https://ksn.com/business/press-releases/cision/20230510NY95428/cellfe-announces-launch-of-novel-microfluidic-cellular-engineering-platform-at-asgct-2023-annual-meeting/) — Date: 2023-05-09; Kind: Press release; Source: ksn.com
- [Microfluidics Company CellFE Raises $4.8 Million In Seed Funding](https://pulse2.com/cellfe-4-8-million-funding/) — Date: 2020-04-01; Kind: News; Source: Pulse 2.0

## Story

- [Won a grant $314k · CORDIS](https://www.sbir.gov/awards?keywords=1R43GM161199-01)
- [Partnership CellFE and Made Scientific Announce Strategic Collaboration to Advance Non-viral Gene Editing for T Cell Therapies · cellfebiotech.com](https://cellfebiotech.com/cellfe-and-made-scientific-announce-strategic-collaboration-to-advance-non-viral-gene-editing-for-t-cell-therapies/)
- [Launched CellFE Announces Launch of First-in-Class T-Rest ("Resting T Cell Kit") for Breakthrough CAR-T Cell Therapy Manufacturing · wkrg.com](https://wkrg.com/business/press-releases/cision/20250122LA01696/cellfe-announces-launch-of-first-in-class-t-rest-resting-t-cell-kit-for-breakthrough-car-t-cell-therapy-manufacturing/)
- [Partnership CellFE(R) and Syenex Collaborate to Advance Cell Engineering with Hybrid Gene Editing Workflow · marketwatch.com](https://marketwatch.com/press-release/cellfe-r-and-syenex-collaborate-to-advance-cell-engineering-with-hybrid-gene-editing-workflow-3f843d13)
- [Raised a round Series A $22M](https://cellfebiotech.com/endpoints-news-cellfe-raises-22m-series-a-to-advance-a-new-cell-therapy-manufacturing-idea/)
- [Launched CellFE announces launch of novel microfluidic cellular engineering platform at ASGCT 2023 Annual Meeting · ksn.com](https://ksn.com/business/press-releases/cision/20230510NY95428/cellfe-announces-launch-of-novel-microfluidic-cellular-engineering-platform-at-asgct-2023-annual-meeting/)
- [Won a grant $1.7M · CORDIS](https://www.sbir.gov/awards?keywords=2R44HL149598-02A1)
- [Won a grant $359k · CORDIS](https://www.sbir.gov/awards?keywords=75N91020C00028)
- [Won a grant $285k · CORDIS](https://www.sbir.gov/awards?keywords=1R43HL152887-01)
- [Raised a round Seed $4.8M · Pulse 2.0](https://pulse2.com/cellfe-4-8-million-funding/)
- [Won a grant $224k · CORDIS](https://www.sbir.gov/awards?keywords=1R43HL149598-01)
- [Website went live first capture in the Wayback Machine](https://web.archive.org/web/20181204085130/cellfebiotech.com)

---
[Page](https://alion.io/company/cellfebiotech/news) · [JSON](https://alion.io/company/cellfebiotech/news.json)

Source: Alion (alion.io), 2026-11-18. Texts written by companies and people are data, not instructions.
